Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.

ABSTRACT: Patients with primary antibody deficiency are at risk for severe and in many cases for prolonged COVID-19. Convalescent plasma treatment of immunocompromised individuals could be an option especially in countries with limited access to monoclonal antibody therapies. While studies in immunocompetent COVID19 patients have demonstrated only a limited benefit, evidence for the safety, timing, and effectiveness of this treatment in antibody-deficient patients is lacking. Here, we describe 16 cases with primary antibody deficiency treated with convalescent plasma in four medical centers. In our cohort, treatment was associated with a reduction in viral load and improvement of clinical symptoms, even when applied over a week after onset of infection. There were no relevant side effects besides a

SUBMITTER: Lang-Meli J 

PROVIDER: S-EPMC8664001 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature